Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash from Operations: 2020-2025

Historic Cash from Operations for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $108.5 million.

  • Apellis Pharmaceuticals' Cash from Operations rose 218.13% to $108.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.9 million, marking a year-over-year increase of 138.45%. This contributed to the annual value of -$87.9 million for FY2024, which is 85.23% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Cash from Operations of $108.5 million as of Q3 2025, which was up 2,340.22% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Cash from Operations registered a high of $108.5 million during Q3 2025, and its lowest value of -$177.6 million during Q1 2023.
  • Over the past 3 years, Apellis Pharmaceuticals' median Cash from Operations value was -$53.4 million (recorded in 2025), while the average stood at -$56.6 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first tumbled by 179.24% in 2021, then skyrocketed by 218.13% in 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Cash from Operations (Quarterly) stood at -$112.5 million in 2021, then declined by 25.11% to -$140.7 million in 2022, then soared by 30.46% to -$97.9 million in 2023, then soared by 119.78% to $19.4 million in 2024, then soared by 218.13% to $108.5 million in 2025.
  • Its last three reported values are $108.5 million in Q3 2025, $4.4 million for Q2 2025, and -$53.4 million during Q1 2025.